Novo Nordisk

Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 54,400 people in 80 countries and markets its products in around 170 countries. For more information visit novonordisk.com.

Our US Research & Development hub, located in the Greater Boston area, brings together the best talent to drive life science innovation. Located in Lexington, Watertown and Cambridge, our teams reflect the full scope of R&D, from early research through late-stage clinical development. We are building for the future by creating a distinct R&D community based on collaboration, partnerships, and cutting-edge research across multiple modalities and therapeutic areas. We recognize that improving human health starts here and that patients rely on us. By combining the speed and agility of biotech with the quality, resources, and stability of a large pharmaceutical company, our US R&D hub will benefit from the best of both worlds to develop new medicines that meet the needs of patients.

Novo Nordisk is its people. We rely on the diversity of perspectives from colleagues all around the world. Our forward thinking, supported by careers that are as dynamic as we are, makes Novo Nordisk a great place to be and be from. This is your moment. Here we don’t stand still, we never give up – we make an impact. We’re trusted to have the courage. Together, we make it happen.

  • 2025 BPTW Badge - RBG.png
  • 2024 Best Places to Work
75 Hayden Avenue
Lexington, MA 02421
  • Featured Employer
NEWS
It didn’t take long for the new leadership structure in the U.S. House of Representatives to take on the pharmaceutical industry. On Monday, the House Committee on Oversight and Reform launched an investigation into prescription drug pricing practices.
The battle of the bulge is ongoing and it appears that Americans are losing, according to a report from the U.S. Centers for Disease Control and Prevention. The report shows that Americans are losing height and gaining girth.
EvaluatePharma and Vantage recently released their Vantage 2019 Preview which looks at the current year’s biopharma market and makes projections about the upcoming year.
BioGeneration Ventures is pleased to announce that its portfolio company Staten Biotechnology B.V. and Novo Nordisk A/S have entered into a collaboration and exclusive option agreement.
Embark was first incubated by Novo Seeds and funded through the pre-seed grant programme of the Novo Nordisk Foundation in 2016
Novo Seeds invests €12.5 million becoming largest shareholder
Indianapolis-based Eli Lilly announced that its diabetes drug Trulicity (dulaglutide) reduced major adverse cardiovascular events (MACE) in its REWIND clinical trial.
NASH is similar to cirrhosis of the liver but occurs in people that drink little or no alcohol. It is related to the obesity epidemic and affects at least three to five percent of the adult population worldwide. Many believe that combination therapies will be the best way to approach treating NASH, because it has several components.
Execs at Novo Nordisk, AbbVie, and more made moves this week. Here’s a roundup of those changes.
JOBS
IN THE PRESS